These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 31587778)

  • 1. Anthracycline Cardiotoxicity: It Is Possible to Teach an Old Dog Some New Tricks.
    Alvarez-Cardona J; Lenihan DJ
    Cardiol Clin; 2019 Nov; 37(4):355-363. PubMed ID: 31587778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiotoxicity of Anthracyclines.
    Cardinale D; Iacopo F; Cipolla CM
    Front Cardiovasc Med; 2020; 7():26. PubMed ID: 32258060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2-i prevent left ventricular dysfunction induced by anthracycline in mouse model: A systematic-review and meta-analysis.
    Faggiano A; Gherbesi E; Cardinale D; Vicenzi M; Carugo S
    Vascul Pharmacol; 2023 Jun; 150():107171. PubMed ID: 37061151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia.
    Stahl M; Giblin G; Liu Y; Winer ES; Garcia JS; Chen E; Wadleigh M; Ling K; Lindsley RC; Shimony S; Copson K; Charles A; DeAngelo DJ; Stone RM; Nohria A; Luskin MR
    Leuk Res; 2023 Sep; 132():107351. PubMed ID: 37451200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between genetic variants of transmembrane transporters and susceptibility to anthracycline-induced cardiotoxicity: Current understanding and existing evidence.
    Ni MM; Yang JF; Miao J; Xu J
    Clin Genet; 2024 Feb; 105(2):115-129. PubMed ID: 37961936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins as preventive therapy for anthracycline cardiotoxicity: a meta-analysis of randomized controlled trials.
    D'Amario D; Laborante R; Bianchini E; Galli M; Ciliberti G; Mennuni M; Patti G
    Int J Cardiol; 2023 Nov; 391():131219. PubMed ID: 37527752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.
    Zhang J; Cui X; Yan Y; Li M; Yang Y; Wang J; Zhang J
    Am J Transl Res; 2016; 8(7):2862-75. PubMed ID: 27508008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment.
    Cai F; Luis MAF; Lin X; Wang M; Cai L; Cen C; Biskup E
    Mol Clin Oncol; 2019 Jul; 11(1):15-23. PubMed ID: 31289672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Oxidative Stress in the Mechanisms of Anthracycline-Induced Cardiotoxicity: Effects of Preventive Strategies.
    Carrasco R; Castillo RL; Gormaz JG; Carrillo M; Thavendiranathan P
    Oxid Med Cell Longev; 2021; 2021():8863789. PubMed ID: 33574985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.
    Aminkeng F; Ross CJ; Rassekh SR; Hwang S; Rieder MJ; Bhavsar AP; Smith A; Sanatani S; Gelmon KA; Bernstein D; Hayden MR; Amstutz U; Carleton BC;
    Br J Clin Pharmacol; 2016 Sep; 82(3):683-95. PubMed ID: 27197003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins for the Primary Prevention of Anthracycline Cardiotoxicity: A Comprehensive Review.
    Bhasin V; Vakilpour A; Scherrer-Crosbie M
    Curr Oncol Rep; 2024 Jul; ():. PubMed ID: 39002055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case of Anthracycline-induced Cardiogenic Shock: A Call to Optimize Modifiable Cardiac Risk Factors Prior to Chemotherapy.
    Gabriel A; Stringer B; Hadfield MJ; Madady M
    Cureus; 2019 Jun; 11(6):e4961. PubMed ID: 31497415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Sodium-Glucose Co-Transporter-2 Inhibitor During Anthracycline Use: An Updated Review.
    Basham HA; Keswani S; Kumar A; Rahol Rai SKA; Surkasha F; Kumari A; Malik J
    Cardiol Rev; 2024 Jan; ():. PubMed ID: 38189378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remote Ischemic Conditioning for Anthracycline Cardiotoxicity: The Need to Protect the Most Vulnerable.
    Ibáñez B; Gomes-Silva M
    JACC CardioOncol; 2023 Jun; 5(3):356-359. PubMed ID: 37397082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthracycline-Induced Cardiotoxicity: Remembering the Forgotten Ventricle.
    Liu JE
    JACC CardioOncol; 2020 Mar; 2(1):23-25. PubMed ID: 34396206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin to Prevent Anthracycline Cardiotoxicity?: That Would Be Sweet!
    El-Rayes M; Nadler MB; Abdel-Qadir H
    JACC CardioOncol; 2023 Oct; 5(5):683-685. PubMed ID: 37969641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity:
    Henriksen PA; Rankin S; Lang NN
    JACC CardioOncol; 2023 Jun; 5(3):292-297. PubMed ID: 37397086
    [No Abstract]   [Full Text] [Related]  

  • 18. New Insight Into Cardioprotection From Anthracyclines: Still Converging on the Mitochondria.
    Chen Q; Meléndez GC; Lesnefsky EJ
    JACC CardioOncol; 2023 Jun; 5(3):374-376. PubMed ID: 37397073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (Less) Time and Energy: Toward a Better Understanding of the Chronology of Anthracycline-Induced Cardiotoxicity.
    Kirkland LG; Jensen BC
    JACC CardioOncol; 2024 Apr; 6(2):233-235. PubMed ID: 38774013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracycline Cardiotoxicity: Can CT Move Us Further?
    Campia U; Nohria A
    JACC CardioOncol; 2020 Jun; 2(2):220-222. PubMed ID: 34396231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.